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2 
Abstract  
 
Heart disease is a major health threat for Duchenne/Becker muscular dystrophy patients 
and carriers.  Expression of a 6 to 8-kb mini-dystrophin gene in the heart holds promise to 
dramatically change the disease course.  However the mini-dystrophin gene cannot be easily 
studied with adeno-associated virus (AAV) gene delivery because the size of the minigene 
exceeds AAV packaging capacity.  We previously studied cardiac protection of the ∆H2-R19 
minigene using the cardiac specific transgenic approach.  Although this minigene fully 
normalized skeletal muscle force, it only partially corrected ECG and heart hemodynamics in 
dystrophin-null mdx mice that had moderate cardiomyopathy.  Here, we evaluated the ∆H2-R15 
minigene using the same transgenic approach in mdx mice that had more severe cardiomyopathy.  
In contrast to the ∆H2-R19 minigene, the ∆H2-R15 minigene carries dystrophin spectrin-like 
repeats 16 to 19 (R16-19), a region that has been suggested to protect the heart in clinical studies.  
Cardiac expression of the ∆H2-R15 minigene normalized all aberrant ECG changes and 
improved hemodynamics.  Importantly, it corrected the end-diastolic volume, an important 
diastolic parameter not rescued by ∆H2-R19 mini-dystrophin.  We conclude that that ∆H2-R15 
mini-dystrophin is a superior candidate gene for heart protection. This finding has important 
implications in the design of the mini/micro-dystrophin gene for Duchenne cardiomyopathy 
therapy. 
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3 
Introduction 
Loss of dystrophin results in Duchenne muscular dystrophy (DMD).  While skeletal 
muscle presentations start at the toddler age, symptoms of myocardial involvement are rarely 
seen before teenage.  Despite the later onset, up to 40% of patients may die from heart failure 
and/or sudden cardiac death 
1-3
.  Currently, there is no etiology-based treatment for Duchenne 
cardiomyopathy.  Gene therapy may solve the fundamental problem of dystrophin deficiency 
4-6
.  
Some serotypes of adeno-associated virus (AAV) have the intrinsic property of reaching all body 
muscles (including the heart) after a single intravascular delivery 
7-11
.  This makes AAV a 
favored vector for DMD gene therapy.  Unfortunately, the dystrophin gene is one of the largest 
genes in the genome and AAV is one of the smallest viruses.  As a matter of fact, the size of the 
full-length dystrophin coding sequence is about three times the size of the AAV genome.  
Development of minimized dystrophin may open the door for AAV-mediated DMD gene 
therapy.  
Dystrophin is a 427-kD rod-shaped protein encoded by 79 exons.  It has four major 
domains.  The N-terminal domain interacts with filamentous cytoskeletal γ-actin.  Immediately 
following the N-terminal domain is the rod domain which accounts for more than 70% of the 
molecular weight of dystrophin.  The rod domain can be further divided in 24 spectrin-like 
repeats (R) and four intervening hinges (H).  The rod domain contains the second actin-binding 
domain and neuronal nitric oxide synthase (nNOS) binding domain.  Towards the carboxyl end 
is the cysteine-rich (CR) domain and the C-terminal domain.  The CR domain interacts with 
transmembrane protein dystroglycan.  The C-terminal domain binds to syntrophin and 
dystrobrevin.  Abbreviated dystrophins have been generated largely based on our understanding 
of the structure-function relationship of dystrophin in skeletal muscle.  Of particular interest is 
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4 
the notion that most part of the rod domain can be deleted without significant consequences on 
function 
12, 13
.  A 6.2-kb ∆17-48 minigene was found in a 61-year-old ambulant patient 
13
.  The 
Chamberlain lab optimized this 6.2-kb minigene into the 6-kb ∆H2-R19 minigene.  Transgenic 
expression of the ∆H2-R19 minigene yielded better skeletal muscle protection than the ∆17-48 
minigene in dystrophin-null mdx mice.  Importantly, ∆H2-R19 mini-dystrophin fully restored 
muscle force 
12, 14
.  In light of these encouraging skeletal muscle data on the ∆H2-R19 minigene 
12, 14
, we generated cardiac specific ∆H2-R19 min-dystrophin transgenic mdx mice 
15
. We studied 
heart protection of ∆H2-R19 min-dystrophin in 21-m-old male mdx mice which show moderate 
cardiomyopathy 
15-18
.  In contrast to what was seen in skeletal muscle 
12, 14
, expression of ∆H2-
R19 min-dystrophin in the heart only partially corrected ECG and cardiac hemodynamic 
deficiencies 
15
.  This unexpected result suggests that ∆H2-R19 mini-dystrophin may lack 
domain(s) important for heart function.   
On reviewing the clinical literature, we found that patients with deletion mutations in the 
region of R16 to R19 often display early onset and/or more severe heart disease 
19-33
.  We 
wondered whether inclusion of R16-19 might lead to a better cardiac protection.  To this end, we 
inserted R16-19 to ∆H2-R19 mini-dystrophin and made ∆H2-R15 mini-dystrophin (Figure 1A).  
We then generated cardiac-specific ∆H2-R15 mini-dystrophin transgenic mice 
15
. To increase the 
stringency of the study, we focused on a more severe model that showed classic end-stage dilated 
cardiomyopathy found in human patients 
16-18, 34
.  Despite the fact that the ∆H2-R15 minigene 
was tested in mice with more severe heart disease, surprisingly, several physiological parameters 
that were not corrected by the ∆H2-R19 minigene in the less severe model were now normalized 
by ∆H2-R15 mini-dystrophin.  Our results suggest that inclusion of R16-19 in synthetic mini-
dystrophins can enhance cardiac rescue.  
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5 
Materials and Methods 
Experimental Animals.  All animal experiments were approved by the institutional animal care 
and use committee and were in accordance with NIH guidelines.  FVB mice were used as the 
wild type control mice.  They were generated in a barrier facility using breeders purchased from 
The Jackson Laboratory (Bar Harbor, ME).  Congenic FVB background mdx mice were 
generated as we described before 
35
.  The transgenic founder lines were generated on the FVB 
background at the University of Missouri transgenic core.  These mice express the ∆H2-R15 
mini-dystrophin gene under the transcriptional control of the cardiac muscle specific α-myosin 
heavy chain (αMHC) promoter.  Mini-dystrophin transgenic mdx mice were generated by 
crossing transgenic found mice with FVB background mdx mice.  Two founder lines (line 271 
and line 272) were generated.  In our studies, we combined the data from both lines in our result 
section because (1) we have previously shown that 5-fold to 50-fold transgenic over-expression 
of mini-dystrophin in the heart yielded similar protection and (2) we did not detect a statistically 
significant difference between these two lines (Supplementary Table 1).  Below we further 
clarify the source of the mice used in each figure.  The representative images for transgenic mice 
in Figure 1 are from line 271 animals.  For the ECG analysis (Figure 2) we have used mice n=22 
from line 271 and n=10 from line 272.  For the left ventricle hemodynamics (Figure 3) we have 
used n=19 from line 271 and n=6 from line 272.  We have used n=3 from lines 271 and 272 for 
the western blot quantification shown in Figure 4.  For the Supplementary figure 1, we have used 
n=2 from line 271 and n=1 from line 272.  The average age of the mice was 23.3±0.20 and 
22.9±.0.05 months for lines 271 and 272 respectively.   For the Supplementary table 1, we have 
used n=19 from line 271 and n=6 from line 272.  All mice were maintained in a specific-
pathogen free animal care facility on a 12-hour light (25 lux):12-hour dark cycle with access to 
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6 
food and water ad libitum.  Mice were euthanized following functional assays to harvest tissues.  
All histology and physiology studies were performed in mice that were 23-m-old (23.22 ± 0.16 
months) (Table 1).  
 
Morphological studies.  Dystrophin expression was evaluated by immunofluorescence staining 
using three independent dystrophin monoclonal antibodies including Dys2 (1:30; Vector 
Laboratories), DysB (1:80, clone 34C5, IgG1; Novocastra) and Mandys8 (1:200; Sigma 
Aldrich).  Dys2 and DysB react with ∆H2-R15 mini-dystrophin.  Mandys8 recognizes an epitope 
in dystrophin repeat 11, which is absent in ∆H2-R15 mini-dystrophin 
36, 37
.  General histology 
was examined by hematoxylin and eosin (HE) staining.  Fibrosis was examined by Masson 
trichrome staining as we described before 
38
.  Slides were viewed at the identical exposure 
setting using a Nikon E800 fluorescence microscope.  Photomicrographs were taken with a 
QImage Retiga 1300 camera 
38
.  The fibrotic tissue deposition was quantified using 
photomicrographs of Masson trichrome stained images using Photoshop Software.  Briefly, the 
measurement scale was set up for the relevant magnification for the microscope and using the 
lasso tool in Photoshop, the fibrotic area was marked in individual images.  The fibrotic area 
from multiple images were averaged per individual animal and the total area of fibrosis is 
calculated for 3-4 animal for each strain.    
 
Western blot.  Whole heart and muscle lysate was prepared as we described before 
39
.  Briefly, 
the tissues were snap frozen in liquid nitrogen.  The frozen tissue samples were ground to fine 
powder in liquid nitrogen followed by homogenization in a buffer containing 10% sodium 
dodecyl sulfate, 5mM ethylenediaminetetraacetic acid, 62.5mM Tris-HCl at pH6.8 and the 
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7 
protease inhibitor cocktail (Roche, Indianapolis, IN).  The crude lysates were heated at 95°C for 
3 min, chilled on ice for 2 min and then centrifuged at 14,000 rpm for 2 min.  Supernatant was 
collected as the whole muscle lysate.  Protein concentration was measured using the DC protein 
assay kit (Bio-Rad, Hercules, CA).  Dystrophin was detected with the Dys2 antibody (1:100, 
Novocastra).  The calcium handling proteins were detected using antibodies against 
sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a, 1:2,500 Badrilla, Leeds 
UK) and phospholamban (1:2,500 Badrilla, Leeds UK).  Proteins involved in cellular signaling 
were detected using antibodies for c-jun N-terminal kinase (JNK1, 1:1,000 BD Pharmingen San 
Jose, CA), p38α (1:500, Santa Cruz Biotechnology, Dallas, TX), Akt (1:1,000, Cell Signaling 
Technology, Danvers, MA), and endothelin-A receptor (ET-A, 1:5,000, Abcam, Cambridge, 
MA).  For the loading control, we used antibodies against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH, 1:3,000; Millipore, Billerica, MA) and vinculin (1:2,000, Abcam, 
Cambridge, MA).   
Western blot quantification was performed using the LI-COR Image Studio Version 
5.0.21 software (https://www.licor.com).  The intensity of the respective protein band was 
normalized to the corresponding loading control in the same blot.  The relative band intensity 
was normalized to the wild type control group. 
 
ECG and hemodynamic assay.  Cardiac functions were evaluated using our published 
protocols as described in the standard operating protocol in the Cardiac Protocols for Duchenne 
Animal Models 
(http://www.parentprojectmd.org/site/PageServer?pagename=Advance_researchers_sops) 
40, 41
.  
Specifically, a 12-lead ECG assay was performed using a commercial system from AD 
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8 
Instruments (Colorado Springs, CO) 
38, 42
.  The Q wave amplitude was determined using the lead 
I tracing.  Other ECG parameters were analyzed using the lead II tracing.  The QTc interval was 
determined by correcting the QT interval with the heart rate as described by Mitchell et al 
43
.  
The cardiomyopathy index was calculated by dividing the QT interval by the PQ segment 
44
.  
Left ventricular hemodynamics was evaluated using a closed chest approach as we have 
previously described 
38, 40
.  The resulting PV loops were analyzed with the PVAN software 
(Millar Instruments, Houston, TX).  
 
Statistical analysis.  Data from individual experimental subject are presented using the scatter 
plots.  Data from the experimental group are presented as mean ± stand error of mean.  One-way 
ANOVA with Bonferroni’s multiple comparison analysis was performed using GraphPad 
PRISM software version 7.0 for Mac OSX (GraphPad Software, La Jolla California USA, 
www.graphpad.com).  A p < 0.05 was considered statistically significant.  
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9 
Results  
 
Generation of αMHC.∆H2-R15 mini-dystrophin transgenic mdx mice.  To study the cardiac 
benefit of ∆H2-R15 mini-dystrophin, we generated cardiac specific αMHC.∆H2-R15 minigene 
transgenic mice (Figure 1A).  Cardiac specific expression was regulated by the αMHC promoter 
and the bovine growth hormone gene polyadenylation sequence.  Two founder lines (line 271 
and line 272) were generated on the FVB background and subsequently crossed to the FVB 
background mdx mice.   
The progression of Duchenne cardiomyopathy undergoes several distinctive phases from 
pre-symptomatic stage to compensatory hypertrophic cardiomyopathy and eventually dilated 
cardiomyopathy 
16, 17
.  We recently discovered that only ≥21-m-old female mdx mice display 
severe end-stage dilated cardiomyopathy 
18
.  Hence, we focused the current study on 23-m-old 
female mdx mice.  Cardiac expression of the ∆H2-R15 minigene was confirmed by dystrophin 
immunofluorescence staining in both founder lines using Dys2, DysB and Mandys8 antibodies.  
DysB and Dys2 recognize H1-R2 and the C-terminal domain, respectively while Mandys8 reacts 
with R11 which is absent in ∆H2-R15 mini-dystrophin (Figure 1B).  Heart lysate western blot 
revealed the right size band at levels 7.5 and 13-folds higher than that of full-length dystrophin in 
a normal heart (Figure 1C).  We have previously shown that transgenic mini-dystrophin 
expression in the mdx heart at 5- to 50-fold higher than that of full-length dystrophin in wild type 
mice yielded similar levels of histological and physiological rescue 
45
.  Hence, quantification 
data presented in the rest of the manuscript are from both lines.  On HE staining and Masson 
trichrome staining, we detected nominal inflammation and fibrosis in the heart of αMHC.∆H2-
R15 mice (Figure 1D, Supplementary Figure 1).  On quantification, the fibrotic area in the 
heart of αMHC.∆H2-R15 mice was significantly lower than that of mdx mice and actually it was 
Page 11 of 43
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Human Gene Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/Not for Distribution
 
 
10
comparable to that of wild type mice (Supplementary Figure 1).  As expected, skeletal muscle 
of αMHC.∆H2-R15 mice had no dystrophin expression and displayed characteristic degeneration 
and fibrosis comparable to those of mdx mice (Figure 1E) 
35
.  
 
∆H2-R15 mini-dystrophin normalized aberrant ECG changes.  To determine therapeutic 
benefits on cardiac electrophysiology, we performed the 12-lead ECG assay 
40, 41
.  Except for the 
lack of tachycardia, we observed all other characteristic ECG abnormalities in transgene-
negative mdx mice (Figure 2).  Specifically, the PR interval was significantly reduced, QRS 
duration and Mitchell’s corrected QT (QTc) interval were significantly prolonged, the absolute 
value of the Q wave amplitude and the cardiomyopathy index were significantly increased 
(Figure 2).  These abnormal changes were completely corrected in αMHC.∆H2-R15 mice 
(Figure 2).  
 
∆H2-R15 mini-dystrophin prevented heart dilation.  Hemodynamics was examined using left 
ventricular catheterization (Figure 3, Supplementary Table 1) 
15, 42
.  Similar to our previous 
report 
18
, we observed characteristic signs of dilated cardiomyopathy such as a significant 
increase of the end systolic volume and end diastolic volume in transgene-negative mdx mice 
(Figure 3).  Transgenic expression of ∆H2-R15 mini-dystrophin in the heart normalized the end-
systolic volume, dP/dt maximum, end-diastolic volume and ejection fraction.  A trend of 
improvement was also seen in the maximal pressure, dP/dt minimum, stroke volume and cardiac 
output (Figure 3).  Nevertheless, the isovolumetric relaxation time constant tau was not 
corrected (Figure 3).  In contrast, the mean tau value was significantly increased compared to 
that of wild type controls.   
Page 12 of 43
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Human Gene Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/Not for Distribution
 
 
11
 
Anatomic examination revealed cardiac hypertrophy in αMHC.∆H2-R15 mice.  At the end 
of in-life study, we measured body weight (BW), heart weight (HW), ventricular weight (VW), 
tibia length (TL) and TA muscle weight (TW) (Table 1).  Compared to that of wild type control, 
TW was significantly reduced in αMHC.∆H2-R15 mice, consistent with skeletal muscle disease-
related limb muscle atrophy.  Interestingly, HW and VW of αMHC.∆H2-R15 mice were 
significantly (~14%) higher than those of wild type controls.  The HW/TW and VW/TW ratios 
of αMHC.∆H2-R15 mice were also significantly increased compared to those of wild type 
control mice, suggesting cardiac hypertrophy in αMHC.∆H2-R15 mice.  Since TW was affected 
by skeletal muscle disease, we evaluated TL normalized HW and VW 
34, 46
.  Compared to those 
of wild type control mice, the HW/TL and VW/TL ratios of αMHC.∆H2-R15 mice were 
significantly higher, thus confirming cardiac hypertrophy in αMHC.∆H2-R15 mice.  
 
Evaluation of calcium handling proteins and cardiac hypertrophy related signaling 
proteins.  To begin to understand the mechanisms of hear  protection by ∆H2-R15 mini-
dystrophin, we quantified the expression of SERCA2a and phospholamban, two important 
calcium handling proteins that are known to regulate heart contractility (Figure 4).  Compared to 
wild type control mice, both SERCA2a and phospholamban appeared reduced in mdx mice.  
Their levels were increased in αMHC.∆H2-R15 mice but did not reach statistical significance.  
 Many signaling pathways have been implicated in cardiac hypertrophy (Reviewed in 
47-
51
).  As the first step towards elucidation of the molecular processes underlying myocardial 
hypertrophy seen in αMHC.∆H2-R15 mice, we examined several proteins in the mitogen-
activated protein kinase (MAPK) pathway, Akt signaling and G-protein coupled receptor 
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12
signaling (Figure 4) 
51-60
.  These pathways have been implicated in either pathological or 
physiological cardiac hypertrophy.  JNK1 and p38α are two important branches of the MAPK 
signaling cascade. We did not detect statistically significant difference (Figure 4).  Endothelin 
receptor A (ET-A) is a G-protein coupled receptor.  Western blot on ET-A and Akt did not show 
noticeable trends (Figure 4).   In light of the substantial individual differences (especially for 
Akt) and the small sample size (n=3 for αMHC.∆H2-R15 mice), we could not draw a solid 
conclusion on the involvement of the Akt signaling and G-protein receptor signaling.   
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13
Discussion  
 Two distinctive strategies have been used to study the structure-function relationship of 
dystrophin, namely the transgenic approach and AAV-mediated gene transfer.  Systemic AAV 
delivery results in simultaneous transduction of both skeletal muscle and heart.  This creates a 
challenge for sorting out cardiac specific effect because it is controversial whether treating 
skeletal muscle can reduce or aggravate heart disease in mdx mice 
38, 61, 62
.  To get a definitive 
answer on the cardiac specific effect, here we opted using the transgenic approach instead of 
AAV delivery to avoid confounding influences from skeletal muscle dystrophin expression.  
 Dystrophin is essential for the survival and function of both skeletal muscle and cardiac 
muscle.  However, recent studies suggest that there may exist important differences between 
skeletal muscle dystrophin and cardiac dystrophin.  For example, dystrophin directly binds to 
neuronal nitric oxide synthase (nNOS) in skeletal muscle and this interaction is critical to the 
sarcolemmal localization of nNOS in skeletal muscle 
14, 63
.  But in cardiac muscle, dystrophin 
dose not interact with nNOS and nNOS is localized in the sarcoplasmic reticulum and 
mitochondria in the heart 
64-67
.  Cytosolic nNOS compromises muscle function in mdx mice by 
inducing nitrosative stress but cytosolic over-expression of nNOS in the heart improves cardiac 
function in aged mdx mice 
39, 67
.  Cardiac dystrophin directly associates with myofibrils at the Z-
disk but skeletal muscle dystrophin does not interact with myofibrils 
68
.  Recent proteomic 
studies have further identified cellular proteins that selectively interact with dystrophin in the 
heart but not in skeletal muscle 
66
.  Collectively, these observations suggest that dystrophin may 
play overlapping but distinctive roles in the heart and skeletal muscle.  It is thus important to 
determine whether a therapeutic candidate dystrophin gene that can protect skeletal muscle can 
also protect the heart.   
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14
The ∆H2-R19 minigene and ∆H2-R15 minigene have both been shown to fully rescue 
skeletal muscle contractility 
12, 14, 69
.  Interestingly, cardiac-specific expression of the ∆H2-R19 
minigene in transgenic mice failed to completely correct ECG abnormalities.  In the 
hemodynamic assay, the ∆H2-R19 minigene also did not correct the end-diastolic volume, an 
important parameter in the context of Duchenne cardiomyopathy.  It was unclear whether the 
∆H2-R15 minigene can lead to better rescue.  To address this question, we generated 
αMHC.∆H2-R15 minigene transgenic mice (Figure 1) and then compared cardiac 
histopathology, anatomy and function among normal, transgene-positive and transgene negative 
mdx mice when they reached 23 months of age.   In the absence of the minigene, mdx mice 
showed ECG and hemodynamic features that are characteristic for dilated cardiomyopathy 
(Figures 2 and 3).  All aberrant ECG changes were normalized in αMHC.∆H2-R15 minigene 
transgenic mice (Figure 2).  On the cardiac catheter assay, the enlarged end-diastolic and end-
systolic volumes were normalized by ∆H2-R15 mini-dystrophin, the reduced dP/dt max was 
returned to the wild type level, and ejection fraction was normalized (Figure 3).  Collectively, 
these results suggest that the ∆H2-R15 minigene is an outstanding candidate gene for treating 
Duchenne dilated cardiomyopathy.   
The exact molecular mechanisms underlying superior cardiac rescue by the ∆H2-R15 
minigene will have to wait until future in-depth studies.   Nevertheless, we speculate that it may 
at least partially due to the presence of R16-19 in this minigene.  Nigro et al studied 284 patients 
and found that deletion of exons 48 and 49 (R19) correlates with severe cardiac disease 
23
.  In a 
more recent study, Kaspar et al analyzed 78 patients and discovered the N-terminal domain and 
R17-19 might protect the heart.  Deletion of one these two regions often result in early onset 
heart disease 
33
.  Numerous clinical studies on Becker muscular dystrophy (a mild form of DMD) 
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15
and X-linked dilated cardiomyopathy (a disease caused by selective dystrophin deficiency in the 
heart) from other groups also pointed towards a potential cardiac protective role of R16-19 
19-33
.   
Our results aligned well with these patient oriented studies.  Collectively, these data suggest that 
R16-19 may represent a putative heart protection domain in dystrophin.  
It is worth noting that the existence of the tissue-specific domain in dystrophin has been 
well documented in the literature.  For example, repeats 16 and 17 are essential for anchoring 
nNOS to the sarcolemma in skeletal muscle 
14
.  The C-terminal domain appears to be required 
for normal electroretinography and mutations in the C-terminal domain often associate with 
cognitive deficiency 
70, 71
.  However, except for the nNOS-binding R16/17 domain for skeletal 
muscle, dystrophin tissue-specific domains have rarely been studied and/or validated in animal 
models.  The study described here is the first to try to experimentally determine whether certain 
regions of dystrophin can result in better heart rescue.  While our results are encouraging, 
additional studies are needed before we can draw a solid conclusion.  Some of these studies may 
include exploration of cardiac-specific dystrophin interacting proteins such as cavin-1 and αB-
crystalline 
66
.  Cavin-1 is particularly interesting because several recent studies suggest that 
cavin-1 deficiency contributes to the pathogenesis of cardiomyopathy and muscular dystrophy 
72-
74
. 
An intriguing finding of our study is the presence of myocardial hypertrophy in 
αMHC.∆H2-R15 mice (Table 1).  While the molecular trigger for cardiac hypertrophy in 
αMHC.∆H2-R15 mice remains elusive (Figure 4), it certainly suggests a reverse of the disease 
course from heart failure associated dilated cardiomyopathy to compensatory hypertrophic 
remodeling 
16, 17
.  
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We would like to point out that we have used the transgenic approach in the hope of (1) 
comparing with our previously published data from αMHC.∆H2-R19 transgenic mdx mice, and 
(2) more clearly delineating the cardiac specific effect of dystrophin R16-19.  However, the 
transgenic approach cannot be directly applied to gene therapy.  While the size of the ∆H2-R15 
minigene (~ 7-kb) exceeds the packaging capacity of a single AAV vector, it can be expressed 
using various dual AAV vector strategies.  Specifically, the minigene expression cassette can be 
split into two parts and separately packaged with two independent AAV virions.  Co-delivery 
and intermolecular recombination would allow expression of the ∆H2-R15 minigene.  Future 
studies with a set of ∆H2-R15 minigene dual AAV vectors will be necessary to further 
corroborate transgenic findings described here.  Alternatively, the therapeutic benefit of R16-19 
may be investigated using AAV-mediated expression of a micro-dystrophin gene.  In this case, 
one will have to engineer a novel synthetic microgene (≤ 4-kb) that contains R16-19.    
In summary, we have provided the first animal study evidence supporting inclusion of 
R16-19 in a therapeutic candidate gene could be beneficial for treating Duchenne 
cardiomyopathy.   
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Figure 1 C-D  
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Figure 1 E  
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Figure Legends 
Figure 1. Heart-specific expression of ∆H2-R15 mini-dystrophin ameliorated cardiac but 
not skeletal muscle pathology.  A, Illustrations of ∆H2-R19 and ∆H2-R15 mini-dystrophin.  
Dotted box marks the region deleted from full-length dystrophin.  Mini-dystrophin expression is 
under the control of the heart-specific α-myosin heavy chain (αMHC) promoter.  B, 
Representative photomicrographs of dystrophin immunofluorescence staining in the heart of wild 
type, mdx and αMHC.∆H2-R15 transgenic mdx mice.  DysB, Dys2 and Mandys8 are dystrophin 
monoclonal antibodies used in the study.  DysB and Dys2 recognize H1-R2 and the C-terminal 
domain of dystrophin, respectively.  The epitope for Mandys8 (R11) is absent in ∆H2-R15 mini-
dystrophin.  C, Representative western blots of dystrophin (Dys2) in the heart of two lines of 
αMHC.∆H2-R15 transgenic mdx mice and normal wild type control mice.  The right panel 
shows dystrophin densitometry quantification.  D, Representative photomicrographs of HE and 
Masson trichrome staining in the heart of wild type, mdx and αMHC.∆H2-R15 transgenic mdx 
mice.  E, Representative photomicrographs of HE, Masson trichrome (MT) and Dys2 
immunofluorescence staining in the tibialis anterior muscle (TA) and diaphragm of wild type, 
mdx and αMHC.∆H2-R15 transgenic mdx mice (top three panels).  The bottom panel shows 
representative dystrophin (Dys2) western blots from skeletal muscle (TA and diaphragm) of wild 
type, mdx and αMHC.∆H2-R15 transgenic mdx mice. 
 
Figure 2. ∆H2-R15 mini-dystrophin completely rescued ECG abnormalities. A, Quantitative 
evaluation of the heart rate, PR interval, QRS duration, QTc interval, Q amplitude and 
cardiomyopathy index.  Asterisk, significantly different from the indicated group.  B, 
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2 
Representative lead II ECG tracing from wild type, mdx and αMHC.∆H2-R15 transgenic mdx 
mice.   The PR interval was reduced in the mdx mouse but normalized in αMHC.∆H2-R15 
transgenic mdx mouse.  C, Representative lead I ECG tracing from wild type, mdx and 
αMHC.∆H2-R15 transgenic mdx mice.   The deep Q wave in the mdx mouse was normalized in 
αMHC.∆H2-R15 transgenic mdx mice. 
 
Figure 3. ∆H2-R15 mini-dystrophin improved the left ventricular hemodynamics.  A, 
Quantitative evaluation of systolic function.  B, Quantitative evaluation of diastolic function.  C, 
Quantitative evaluation of overall heart function in wild type, mdx and αMHC.∆H2-R15 
transgenic mdx mice.  Asterisk, significantly different from the indicated group.  D, Selected 
pressure-volume loops from wild type, mdx and αMHC.∆H2-R15 transgenic mdx mice.  
Different scenarios (including some extreme cases) are presented to reflect individual 
differences.  For example, in the top right panel the PV loop from the transgenic mouse is almost 
identical to that of a normal mouse but the PV loop from the mdx mouse does not show the 
typical enlargement of the end-diastolic volume.  The top left panel is the representative PV 
loops from all experimental groups. 
 
Figure 4.  Evaluation of calcium handling proteins and cardiac hypertrophy-related 
signaling proteins.  A, Representative immunoblots for sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2a (SERCA2a), phospholamban (PLN), c-jun N-terminal kinase 1 (JNK1), 
endothelin receptor A (ET-A).  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 
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3 
vinculin was used the loading control.  B, Densitometry quantification of the expression level 
(N=3-6 for each group).  
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Tables 
 
Table 1. Weights and weight ratios 
    
  FVB   Mdx/FVB   αMHC.∆H2-R15   
Sample Size (N) 25   13   38   
Age (m) 23.50 ± 0.17  21.03 ± 0.32
a
  23.22 ± 0.16  
BW (g) 29.05 ± 1.11 
 
27.08 ± 1.03 
 
30.13 ± 1.10 
 
HW (mg) 113.16 ± 3.23 
 
122.28 ± 3.97 
 
128.38 ± 3.09
b
 
 
VW (mg) 103.20± 3.05 
 
112.59 ± 3.60 
 
118.95 ± 2.83
b
 
 
TL (mm) 18.79 ± 0.08 
 
19.05 ± 0.07 
 
18.90 ± 0.05 
 
TW (mg) 36.79 ± 0.90
a
 
 
32.35 ± 0.96 
 
31.83 ± 0.86 
 
HW/BW (mg/g) 4.00 ± 0.15 
 
4.57 ± 0.18 
 
4.34 ± 0.13 
 
HW/TL (mg/mm) 6.02 ± 0.17 
 
6.38 ± 0.21 
 
6.58 ± 0.16
b
 
 
HW/TW (mg/g) 3.09 ± 0.08
a
 
 
3.81 ± 0.13 
 
4.12 ± 0.12 
 
VW/BW (mg/g) 3.66 ± 0.14 
 
4.20 ± 0.16 
 
4.02 ± 0.12 
 
VW/TL (mg/mm) 5.48 ± 0.16 
 
5.89 ± 0.19 
 
6.10 ± 0.15
b
 
 
VW/TW (mg/g) 2.81 ± 0.07
a
   3.51 ± 0.12   3.82 ± 0.11 
 
 
Abbreviations: BW, body weight; HW, heart weight; VW, ventricle weight; TL, tibia length; 
TW, anterior tibialis muscle weight. 
a
, significantly different from other two groups  
b
, significantly different from FVB  
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Supplementary Figure legend 
 
Supplementary Figure 1.  Myocardial fibrosis is significantly reduced in αMHC.∆H2-R15 
transgenic mice.  A, Representative photomicrographs of whole heart cross section of Masson 
trichrome staining.  B, Quantification of area of fibrosis in each strain. The left panel shows the 
absolute area of fibrotic area in the heart and the right panel shows the percentage of fibrotic area 
in the whole heart cross section.  
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Supplementary Table 
 
 
Supplementary Table 1.  Hemodynamic comparison of two transgenic lines with wild type and mdx included as references. 
 
        Wild type   Mdx   
αMHC.∆H2-R15 
L271 
  
αMHC.∆H2-R15 
L272 
Sample Size (N)        19 
 
 13             19 
 
          6 
ESV (µL) 6.79± 1.35 
 
16.19 ± 2.43 
 
7.30± 1.15 
 
6.91 ± 1.76 
MaxP (mmHg) 89.36 ± 2.7 
 
81.93 ± 2.69 
 
89.92 ± 2.05 
 
90.46 ± 2.90 
dP/dt max (KmmHg/sec) 11.40 ± 0.36 
 
9.40± 0.46 
 
11.80 ± 0.43 
 
10.88± 0.83 
EDV (µL) 18.89 ± 1.73 
 
23.83± 2.72 
 
17.84 ± 1.36 
 
16.87 ± 2.02 
dP/dt min (mmHg/sec) -8.90 ± 0.30 
 
-7.20 ± 0.68 
 
-8.21 ± 0.32 
 
-6.95 ± 0.68 
Tau (ms) 8.66 ± 0.43 
 
10.26 ± 0.65 
 
12.24 ± 0.47 
 
13.02 ± 1.72 
SV (µL) 14.30 ± 0.91 
 
10.71 ± 1.01 
 
12.24 ± 0.93 
 
11.93 ± 1.94 
EF (%) 72.54 ± 0.91 
 
44.51 ± 3.49 
 
66.42 ± 4.41 
 
64.62 ± 8.04 
CO (mL/sec) 8.45 ± 0.54   6.11± 0.56   7.36 ± 0.55   6.66± 1.18 
 
ESV, end systolic volume; MaxP, maximum pressure; dP/dt max, maximum dP/dt; EDV, end-diastolic volume; dP/dt min, minimum 
dP/dt; Tau, isovolumetric relaxation time constant; SV, stroke volume; EF, ejection fraction; CO, cardiac output.  The statistical 
analysis between the two transgenic lines (line L271 and line L272) failed to yield any significant difference between the two lines.  
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